RIGVIR. Advanced Cancer Treatment
RIGVIR. Oncolytic Virotherapy
Acral Lentiginous Melanoma
Uncontrolled growth of melanocytes, pigment cells found in the epidermal layer of skin, is called a MELANOMA or skin cancer
RIGVIR® Oncolytic Virotherapy. Advanced Cancer Treatment
Oncolytic virotherapy is an effective cancer treatment using special viruses, capable of finding and destroying malignant tumour cells in the body. Rigvir is the first registered and still the one and only genetically unmodified virus available worldwide.
After being administered, the virus finds and infects malignant tumour cells in a process called oncotropism. The virus replicates itself in the cells of a malignant tumour destroying them in a process called oncolysis. Viruses not only destroy cancer cells but also activate the body’s natural immune system, which also targets the malignant cells.
The goal of virotherapy, not unlike that of radiation therapy and chemotherapy, is to destroy cancer cells.
Virotherapy is recognised as a safe and efficient cancer treatment method.
More information here
Oncolytic virotherapy is an official, innovative, and effective cancer treatment using a special virus, which is capable of finding and destroying cells of a malignant tumor in the human body. The medicinal product is intramuscularly injected into a body.
Virotherapy takes place on an in-patient or out-patient basis, depending on the situation and patient’s health condition. The treatment takes place pursuant to tailor-made treatment protocol and in accordance with the application guidelines under the supervision of the doctor. The average treatment period is 3 years during which regular monitoring of analyses and a patient observation takes place.
Cancer virotherapy is a treatment method that is gentle to the body and has minimum side effects. The most common side effect is slightly increased body temperature (up to 37.5°C, 99.5°F) lasting one to three days.
To see testimonials about virotherapy see here
Rigvir® For Cancer Treatment Is A Virus Affecting Only Malignant Cells And Causing No Side Effects
Studies circulating around Rigvir® (short for “Riga virus”) started in the mid-1950s in Latvia by a microbiologist professor Aina Muceniece. The scientist was the first to discover a cancer-killing feature of the drug with little or no side effects.
Patients from roughly 25 countries around the world have started using Rigvir® to treat:
Melanoma, Lung cancer, Various types of sarcoma, Neuroendocrine tumors, Glioblastoma, Ovarian cancer, Uterine cancer, Breast cancer, Bladder cancer, Prostate cancer, Kidney cancer, Pancreatic cancer, Colorectal cancer
Rigvir® affects only cancer cells and destroys them from within leaving normal cells untouched. It is stored in vials for future injection. The explanation may be hard to perceive, that’s why we also have a 5-minute video for you to see how Rigvir® works.
What Clinical Trials Say About Rigvir®: Prolonging Life To Melanoma, Lung Cancer And Sarcoma Patients
A medical journal APMIS (Acta Pathologica, Microbiologica et Immunologica Scandinavica) published in July 2016 the results of clinical trials conducted for patients diagnosed with stage IV melanoma with metastases, stage IIIA small cell lung cancer, and stage 4 histiocytic sarcoma. They look as follows:
“All patients started Rigvir® treatment within a few months after being diagnosed and are currently continuing Rigvir® treatment… Using current standard treatments, the survival of patients with the present diagnoses is low. In contrast, the patients described here were diagnosed 3.5, 7.0, and 6.6 years ago, and their condition has improved and been stable for over 1.5, 6.5, and 4 years, respectively. These observations suggest that virotherapy using Rigvir® can successfully be used in the long-term treatment of patients with melanoma stage IV M1c, small cell lung cancer stage IIIA, and histiocytic sarcoma stage IV…”
Please get in touch with us to be qualified for RIGVIR® therapy:
Doctor Yuri Nikolenko, MD, Ph.D, Rehabilitation
Following are the documents that shall be submitted to us for the assessment (firstname.lastname@example.org):
Full Blood Count